Related Experiment Video

Updated: May 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

[Advanced research of mTOR and lung carcinoid tumors]

Zixuan Zhang1, Mengzhao Wang

  • 1Department of Respiratory Diseases, Peking Union Medical college Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|January 19, 2013
PubMed

Insights

The mammalian target of rapamycin (mTOR) pathway is highly expressed in neuroendocrine tumors. Targeting this pathway offers a promising new anticancer therapy strategy beyond surgery.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The mammalian target of rapamycin (mTOR) is a key protein kinase within the phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway.
  • This pathway regulates critical cellular functions such as proliferation, differentiation, apoptosis, tumorigenesis, and angiogenesis.

Purpose of the Study:

  • To investigate the role of the mTOR pathway in neuroendocrine tumors.
  • To evaluate the potential of targeting the mTOR pathway for novel anticancer therapies.

Main Methods:

  • Analysis of mTOR and related kinase expression in neuroendocrine tumors.
  • Review of existing literature on mTOR pathway inhibitors in cancer treatment.

Main Results:

  • High expression levels of mTOR and mTOR-related kinases were observed in neuroendocrine tumors.
  • The mTOR pathway's involvement in key cellular processes suggests its significance in tumor development.

Conclusions:

  • The mTOR signaling pathway is a relevant target for therapeutic intervention in neuroendocrine tumors.
  • Targeting the mTOR pathway presents a viable alternative or complementary strategy to surgical treatment for these cancers.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...